Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Revenue | $5,261 | $7,112 | $9,556 | $7,296 |
| % Growth | -26% | -25.6% | 31% | – |
| Cost of Goods Sold | $2,096 | $2,217 | $2,989 | $3,201 |
| Gross Profit | $3,165 | $4,896 | $6,566 | $4,095 |
| % Margin | 60.2% | 68.8% | 68.7% | 56.1% |
| R&D Expenses | $12 | $158 | $229 | $134 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,183 | $7,348 | $10,179 | $10,101 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,195 | $7,507 | $10,407 | $10,235 |
| Operating Income | -$2,030 | -$2,611 | -$3,841 | -$6,140 |
| % Margin | -38.6% | -36.7% | -40.2% | -84.1% |
| Other Income/Exp. Net | -$1,037 | -$1,218 | $170 | -$6,632 |
| Pre-Tax Income | -$3,067 | -$3,829 | -$3,671 | -$12,772 |
| Tax Expense | $0 | $66 | $5,667 | -$3,186 |
| Net Income | -$3,044 | -$3,895 | -$9,338 | -$9,586 |
| % Margin | -57.9% | -54.8% | -97.7% | -131.4% |
| EPS | -0.11 | -0.15 | -0.39 | -0.43 |
| % Growth | 26.7% | 61.5% | 9.3% | – |
| EPS Diluted | -0.11 | -0.15 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 27,218 | 26,386 | 23,829 | 22,155 |
| Weighted Avg Shares Out Dil | 27,218 | 26,386 | 23,829 | 22,155 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $11 | $0 |
| Interest Expense | $1,174 | $1,229 | $0 | $2,200 |
| Depreciation & Amortization | $231 | $402 | $412 | $436 |
| EBITDA | -$1,663 | -$2,198 | -$3,429 | -$10,137 |
| % Margin | -31.6% | -30.9% | -35.9% | -138.9% |